• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Sema4 Holdings Corp.

    8/8/23 4:20:01 PM ET
    $SMFR
    Retail: Computer Software & Peripheral Equipment
    Technology
    Get the next $SMFR alert in real time by email
    S-8 1 genedx-formsx82023induceme.htm S-8 Document

    As filed with the Securities and Exchange Commission on August 8, 2023
    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM S-8
    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
    GENEDX HOLDINGS CORP.
    (Exact Name of Registrant as Specified in Its Charter)
    Delaware85-1966622
    (State or Other Jurisdiction
    of Incorporation or Organization)
    (I.R.S. Employer
    Identification No.)

    333 Ludlow Street, North Tower
    Stamford, Connecticut 06902
    (Address of Principal Executive Offices) (Zip Code)
    GENEDX HOLDINGS CORP. 2023 EQUITY INDUCEMENT PLAN
    (Full Title of the Plans)

    Katherine Stueland
    Chief Executive Officer
    333 Ludlow Street, North Tower, 6th Floor
    Stamford, Connecticut 06902
    (Name and Address of Agent For Service)
    (800) 298-6470
    (Telephone Number, including area code, of agent for service)

    Copies to:
    Ethan Skerry
    Per B. Chilstrom
    Fenwick & West LLP
    902 Broadway
    New York, New York 10010
    (212) 430-2600
    Katherine Stueland
    Chief Executive Officer
    GeneDx Holdings Corp.
    333 Ludlow Street, North Tower, 6th Floor
    Stamford, Connecticut 06902
    (800) 298-6470
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer ☐
    Accelerated filer ☒
    Non-accelerated filer☐
    Smaller reporting company ☒
    Emerging growth company ☒
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐





    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information called for by Part I of Form S-8 is omitted from this Registration Statement in accordance with Rule 428 of the Securities Act of 1933, as amended (the “Securities Act”), and the instructions to Form S-8. In accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”) and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plan covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.





    PART II
    Information Required in the Registration Statement
    Item 3.    Incorporation of Documents by Reference.
    The following documents filed by GeneDx Holdings Corp. (the “Registrant”) with the Commission pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:
    (a)the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “2022 Annual Report on Form 10-K”), filed with the Commission on March 16, 2023;

    (b)the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, filed with the Commission on May 9, 2023;
    (c)the Registrant’s Current Reports on Form 8-K filed with the Commission on  January 9, 2023 (but only with respect to Item 5.03 thereto and Exhibits 3.1 and 3.2 thereto), January 30, 2023, February 14, 2023, April 14, 2023, April 17, 2023, April 28, 2023, May 22, 2023, June 20, 2023 and July 24, 2023;

    (d)the Registrant’s Definitive Proxy Statement on Schedule 14A filed with the Commission on April 28, 2023 (but only with respect to information required by Part  III of the 2022 Annual Report on Form 10-K); and

    (c) the description of  the Registrant’s Class A Common Stock contained in the Registrant’s Registration Statement on Form 8-A filed with the Commission on August 31, 2020, as updated by the description of the Registrant’s Class A Common Stock contained in Exhibit 4.4 to the Registrant’s 2022 Annual Report on Form 10-K, including any subsequent amendments or reports filed for the purpose of updating such description.
    All documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to the Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of the filing of such documents, except that information furnished to the Commission under Item 2.02 or Item 7.01 in Current Reports on Form 8-K and any exhibit relating to such information, shall not be deemed to be incorporated by reference in this Registration Statement.
    Any statement contained herein or in a document incorporated or deemed to be incorporated by reference in this Registration Statement shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration Statement, or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this Registration Statement, modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
    Item 4. Description of Securities.

    Not applicable.
    Item 5. Interests of Named Experts and Counsel.

    Not applicable.
    Item 6. Indemnification of Directors and Officers.
    The Registrant is incorporated under the laws of the State of Delaware. Section 145 of the Delaware General Corporation Law authorizes a court to award, or a corporation’s board of directors to grant, indemnity to directors and officers under certain circumstances and subject to certain limitations. The terms of Section 145 of the Delaware General Corporation Law are sufficiently broad to permit indemnification under certain circumstances for liabilities, including reimbursement of expenses incurred, arising under the Securities Act.



    The Registrant’s third amended and restated certificate of incorporation (as amended, the “Certificate of Incorporation”) and amended and restated bylaws (as amended, the “Bylaws”) provide that the Registrant will indemnify its directors and officers, and may indemnify its employees and other agents, to the fullest extent permitted by the Delaware General Corporation Law. However, Delaware law prohibits the Certificate of Incorporation from limiting the liability of the Registrant’s directors for the following:
    •any breach of the director’s duty of loyalty to us or our stockholders;
    •acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
    •unlawful payment of dividends or unlawful stock repurchases or redemptions; and
    •any transaction from which the director derived an improper personal benefit.
    In addition, the Registrant has entered into, and intends to continue to enter, into indemnification agreements with each of its directors and executive officers and certain other key employees, whereby the Registrant has agreed to indemnify its directors, executive officers, and such other key employees against any and all expenses incurred by that director, executive officer, or other key employee because of his or her status as one of the Registrant's directors, executive officers, or other key employees, to the fullest extent permitted by Delaware law, the Certificate of Incorporation and Bylaws. In addition, the indemnification agreements provide that, to the fullest extent permitted by Delaware law, the Registrant will advance all expenses incurred by its directors, executive officers, and other key employees in connection with a legal proceeding involving his or her status as a director, executive officer, or key employee.
    The Registrant currently carries liability insurance for its directors and executive officers for securities matters.
    The indemnification provisions in the Certificate of Incorporation and Bylaws and the indemnification agreements to be entered into between the Registrant and each of its directors and executive officers are sufficiently broad to permit indemnification of the Registrant’s directors and executive officers for liabilities arising under the Securities Act.
    See also the undertakings set out in response to Item 9 hereof.
    Item 7. Exemption From Registration Claimed.
    Not applicable.



    Item 8. Exhibits.
    Exhibit
    Number
    Incorporated by Reference
    Filed
    Herewith
    Exhibit DescriptionFormFile No.ExhibitFiling Date
    4.1
    Third Amended and Restated Certificate of Incorporation of GeneDx Holdings Corp.
    8-K001-394823.1July 28, 2021
    4.2
    First Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of GeneDx Holdings Corp.
    8-K001-394823.1May 2, 2022
    4.3
    Second Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of GeneDx Holdings Corp.
    8-K001-394823.1January 1, 2023
    4.4
    Third Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of GeneDx Holdings Corp.
    8-K001-394823.1April 17, 2023
    4.5
    Fourth Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of GeneDx Holdings Corp.
    8-K001-394823.1April 28, 2023
    4.6
    Amended and Restated Bylaws of GeneDx Holdings Corp., as currently in effect.
    8-K001-394823.2January 9, 2023
    5.1
    Opinion of Fenwick & West LLP.
    X
    23.1
    Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm for GeneDx Holdings Corp.
    X
    23.2
    Consent of Fenwick & West LLP (contained in Exhibit 5.1).
    X
    24.1Power of Attorney (included on the signature page of this Registration Statement).X
    99.1
    GeneDx Holdings Corp. 2023 Equity Inducement Plan.
    8-K001-3948210.1July 24, 2023
    99.2
    Form of Option Award Agreement under the 2023 Equity Inducement Plan.
    8-K001-39482
    10.2
    July 24, 2023

    99.3
    Form of Restricted Stock Unit Award Agreement under the 2023 Equity Inducement Plan.
    8-K001-39482
    10.3
    July 24, 2023

    107
    Filing Fee Table
    X





    Item 9. Undertakings.
    A.The undersigned Registrant hereby undertakes:

    (1) to file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i) to include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii) to reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in the volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20-percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and

    (iii) to include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

    provided, however, that paragraphs A(1)(i) and A(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

    (2) that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3) to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    B. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    C. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that, in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling



    person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered hereby, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.




    SIGNATURES
    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Stamford, State of Connecticut, on the 8th day of August, 2023.

    GENEDX HOLDINGS CORP.
    By:
    /s/ Katherine Stueland
    Katherine Stueland
    Chief Executive Officer









    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Katherine Stueland, Jason Ryan and Kevin Feeley, and each of them, as his or her true and lawful attorneys-in-fact, proxies and agents, each with full power of substitution and resubstitution and full power to act without the other, for him or her in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule 462(b) increasing the number of securities for which registration is sought), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact, proxies and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, proxies and agents, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

    SignatureTitleDate
    /s/ Katherine Stueland
    Chief Executive Officer and Director
    (Principal Executive Officer)
    August 8, 2023
    Katherine Stueland
    /s/ Kevin Feeley
    Chief Financial Officer
    (Principal Financial Officer & Principal Accounting Officer)
    August 8, 2023
    Kevin Feeley
    /s/ Joshua Ruch
    DirectorAugust 8, 2023
    Joshua Ruch

    /s/ Emily LeproustDirectorAugust 8, 2023
    Emily Leproust
    /s/ Richard C. Pfenniger, Jr.DirectorAugust 8, 2023
    Richard C. Pfenniger, Jr.



    Get the next $SMFR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SMFR

    DatePrice TargetRatingAnalyst
    12/7/2022$3.00 → $1.00Buy → Neutral
    Goldman
    8/16/2022$4.00 → $2.00Buy → Hold
    Jefferies
    6/2/2022$3.50Buy
    Goldman
    11/19/2021$12.00Buy
    Goldman Sachs
    10/8/2021$12.00Buy
    BTIG Research
    9/30/2021$13.00Outperform
    Cowen & Co.
    9/24/2021$13.00Buy
    Jefferies
    More analyst ratings

    $SMFR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sema4 Holdings Corp downgraded by Goldman with a new price target

      Goldman downgraded Sema4 Holdings Corp from Buy to Neutral and set a new price target of $1.00 from $3.00 previously

      12/7/22 8:08:36 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Sema4 Holdings Corp downgraded by Jefferies with a new price target

      Jefferies downgraded Sema4 Holdings Corp from Buy to Hold and set a new price target of $2.00 from $4.00 previously

      8/16/22 7:58:53 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Goldman resumed coverage on Sema4 Holdings Corp with a new price target

      Goldman resumed coverage of Sema4 Holdings Corp with a rating of Buy and set a new price target of $3.50

      6/2/22 7:21:25 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    Leadership Updates

    Live Leadership Updates

    See more
    • Sema4 Appoints Healthcare and Diagnostics Industry Veteran Kevin Feeley as Chief Financial Officer

      STAMFORD, Conn., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced that the Company has appointed Kevin Feeley as Chief Financial Officer (CFO), completing its previously announced search for the CFO position. Mr. Feeley, who has held the roles of Senior Vice President of Operations and Head of GeneDx at Sema4 since May 2022, will also continue to lead all key operational aspects of the Company. "As we shared during our recent earnings call, our new management team is committed to profitable growth, efficiency, and scale. Kevin's broad industry experience and successful financial leadership of GeneDx during an accelerated phase of commercial

      8/26/22 8:00:00 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Sema4 Announces Chief Financial Officer Transition Plan

      Appoints Richard Miao, Sema4's Deputy Chief Financial Officer, as interim Chief Financial Officer Reiterates the financial guidance provided on May 12, 2022 STAMFORD, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced its Chief Financial Officer (CFO), Isaac Ro, will be leaving the company on August 9, 2022. Effective immediately, Richard Miao, Sema4's Deputy CFO, will serve as interim CFO while the company conducts a search for a permanent CFO. Mr. Ro will provide consulting services to Sema4 for six months to facilitate a smooth transition of responsibilities. "We are extremely thankful fo

      6/14/22 4:30:00 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $SMFR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ryan Jason bought $161,368 worth of shares (114,742 units at $1.41) (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      11/20/23 4:32:17 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Pfenniger Richard C Jr bought $14,889 worth of shares (10,000 units at $1.49), increasing direct ownership by 92% to 20,918 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      11/8/23 7:19:00 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance

      Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis® platforms Company's common stock will trade on the Nasdaq under new ticker "WGS" effective January 10, 2023 STAMFORD, Conn, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR) today announced it has changed its name from Sema4 Holdings Corp. to GeneDx Holdings Corp. GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic and clinical insights, is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx's industry-leading exome and

      1/9/23 8:30:00 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference

      STAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced the company will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco. Katherine Stueland, President and Chief Executive Officer, will deliver a formal presentation on Thursday, January 12, 2023, at 10:30 a.m. PT. A live and archived webcast of the presentation will be available on the "Events" section of the Sema4|GeneDx investor relations website at https://ir.sema4.com/. About Sema4|GeneDx Sema4|GeneDx is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming

      12/30/22 8:30:00 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU

      STAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The findings support the addition of mitochondrial DNA (mtDNA) testing to rapid exome sequencing, showing it can lead to earlier diagnoses and more immediate potential changes in clinical management. The research evaluates the incidence of mitochondrial disease caused by both nuclear DNA (nDNA) and mtDNA in 966 infants in the NICU who received both rapid exome sequencing and mtDNA sequencing and deletion testing concurrently. Mitochondrial diseases are chronic, genetic disorders that occur when mitochondria fai

      12/5/22 8:00:00 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Saad Kareem sold $625 worth of shares (193 units at $3.24) and converted options into 546 shares, increasing direct ownership by 1% to 24,467 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      1/23/24 4:10:20 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Ryan Jason gifted 73,614 shares, closing all direct ownership in the company (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      1/12/24 4:31:01 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Saad Kareem sold $271 worth of shares (105 units at $2.58), decreasing direct ownership by 0.43% to 24,114 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      1/4/24 5:03:07 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    Financials

    Live finance-specific insights

    See more
    • Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance

      Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis® platforms Company's common stock will trade on the Nasdaq under new ticker "WGS" effective January 10, 2023 STAMFORD, Conn, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR) today announced it has changed its name from Sema4 Holdings Corp. to GeneDx Holdings Corp. GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic and clinical insights, is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx's industry-leading exome and

      1/9/23 8:30:00 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction

      Company will focus on its high growth, high margin pediatric and rare disease business, powered by whole exome/genome diagnostic testing and analysis and data-driven insights from Centrellis® 19% pro forma1 volume growth vs. 3Q 2021 and 21% pro forma1 revenue growth vs. 3Q 2021 Sema4 to host a conference call today at 8:30 a.m. ET STAMFORD, Conn., Nov. 14, 2022 (GLOBE NEWSWIRE) --  Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), a health insights company, today announced business highlights and financial results for the third quarter ended September 30, 2022. Additionally, Sema4 announced its decision to pursue a new strategic direction focused on a $30 billion market opportunity

      11/14/22 8:02:00 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022

      STAMFORD, Conn., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced it will release financial results for the third quarter of 2022 before the market opens on Monday, November 14, 2022. On the same day, Katherine Stueland, Chief Executive Officer of Sema4, and Kevin Feeley, Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Sema4 will host a conference call on November 14, 2022, at 8:30 a.m. Eastern Time. Interested parties may access the live teleconference by dialing (866) 374-5140, followed by PIN 44463501#. A live and archived webcast

      11/4/22 4:05:00 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    SEC Filings

    See more
    • Sema4 Holdings Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - GeneDx Holdings Corp. (0001818331) (Filer)

      1/8/24 8:58:39 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form 144 filed by Sema4 Holdings Corp.

      144 - GeneDx Holdings Corp. (0001818331) (Subject)

      11/15/23 5:17:42 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form 10-Q filed by Sema4 Holdings Corp.

      10-Q - GeneDx Holdings Corp. (0001818331) (Filer)

      11/3/23 4:06:35 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Sema4 Holdings Corp.

      SC 13G - GeneDx Holdings Corp. (0001818331) (Subject)

      2/9/24 7:10:06 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form SC 13D/A filed by Sema4 Holdings Corp. (Amendment)

      SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

      11/17/23 4:15:23 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form SC 13G/A filed by Sema4 Holdings Corp. (Amendment)

      SC 13G/A - GeneDx Holdings Corp. (0001818331) (Subject)

      6/9/23 4:15:22 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology